2016
DOI: 10.1016/j.coche.2016.01.005
|View full text |Cite
|
Sign up to set email alerts
|

The incorporation of microfluidics into circulating tumor cell isolation for clinical applications

Abstract: The second leading cause of death in the United States, cancer is at its most dangerous as it spreads to secondary locations. Cancer cells in the blood stream, or circulating tumor cells (CTCs), present an opportunity to study metastasis provided they may be extracted successfully from blood. Engineers have accelerated the development of technologies that achieve this goal based on exploiting differences between tumor cells and surrounding blood cells such as varying expression patterns of membrane proteins or… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 45 publications
(61 reference statements)
0
11
1
Order By: Relevance
“…The clinical significance of CTCs has been shown in multiple cancers, including prostate cancer, in which the prognostic values of CTC counts above and below the cut-off of 5 CTCs/7.5 mL whole blood have been associated with overall survival (15). Beyond enumeration, novel CTC isolation technologies have also enabled further characterization, including protein expression by immunofluorescence (16,17). …”
Section: Introductionmentioning
confidence: 99%
“…The clinical significance of CTCs has been shown in multiple cancers, including prostate cancer, in which the prognostic values of CTC counts above and below the cut-off of 5 CTCs/7.5 mL whole blood have been associated with overall survival (15). Beyond enumeration, novel CTC isolation technologies have also enabled further characterization, including protein expression by immunofluorescence (16,17). …”
Section: Introductionmentioning
confidence: 99%
“…This problem has been addressed with a host of isolation technologies . Notably, the first FDA‐approved CTC isolation technology, CellSearch, has been used to establish survival differences based on CTC enumeration .…”
Section: Introductionmentioning
confidence: 99%
“…El-Heliebi et al compared three different CTC isolation systems for gene expression and DNA mutation analysis in CTCs of prostate cancer patients and showed also differences 32 . The incorporation of microfluidics into CTC isolation is now emerging for clinical applications 33 . Many microfluidic technologies have reported high sensitivity and specificity for capturing CTCs, however, the question still remains as to the superiority in comparison to immunoaffinity based approaches, specifically to identify different CTC populations 34 .…”
Section: Discussionmentioning
confidence: 99%